NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BETA · data 2026-10-30
Beta Drugs Ltd.
In plain words
Price: 36.0% below its 52-week high of ₹2,807.9.
Delivery: 38.8% of traded shares were kept for delivery over the last 10 sessions, against 49.2% over the last 60.
Latest results: a net profit of ₹17 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹444 cr |
| Net profit (last 12 months) | ₹52 cr |
| Sales growth, 3 years (yearly) | 19.2% |
| Profit growth, 3 years (yearly) | 10.5% |
Latest results in brief (Q1 FY27)
BETA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹125.55 crore, up 33.6% QoQ.
Net profit was ₹17.17 crore, up 89.7% QoQ.
Operating margin was 21.8%.
EPS was ₹14.78, up 65.5% QoQ.
BETA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹125.55 करोड़; पिछली तिमाही की तुलना में 33.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹17.17 करोड़; पिछली तिमाही की तुलना में 89.7% की बढ़त।
ऑपरेटिंग मार्जिन: 21.8%।
EPS: ₹14.78; पिछली तिमाही की तुलना में 65.5% की बढ़त।
BETAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹125.55 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 33.6% વધારો.
ચોખ્ખો નફો: ₹17.17 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 89.7% વધારો.
ઓપરેટિંગ માર્જિન: 21.8%.
EPS: ₹14.78; ગયા ક્વાર્ટરની સરખામણીએ 65.5% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
18/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 32.4% over the last 20 sessions vs 50.1% in the 40 before (0.65x); shares delivered per day 1.88x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 20 Jul 26Results Q1 FY27 results: net profit ₹17.2 cr +11.2% next session
- 14 May 26Results Q4 FY26 results: net profit ₹9.1 cr -10.2% next session
- 14 Feb 26Results Q3 FY26 results: net profit ₹8.5 cr -17.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹126 cr | ₹17 cr | — | 21.8% | 14.78 |
| Mar 2026 | ₹94 cr | ₹9 cr | — | 18.8% | 8.93 |
| Dec 2025 | ₹87 cr | ₹9 cr | — | 19.5% | 8.4 |
Common questions
What was Beta Drugs Ltd.'s latest quarterly profit?
Beta Drugs Ltd. reported a net profit of ₹17 cr for the quarter ended Jun 2026, on revenue of ₹126 cr.
Is Beta Drugs Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.62.
What is Beta Drugs Ltd.'s P/E ratio?
About 36.9, based on the last 12 months' earnings and a price of ₹1,798.4 (data 2026-10-30).
What is the 52-week high and low of Beta Drugs Ltd.?
The 52-week high is ₹2,807.9 and the 52-week low is ₹990.1.
Similar companies
Sakar Healthcare Ltd (SAKAR) · Panacea Biotec Limited (PANACEABIO) · Hester Biosciences Limited (HESTERBIO) · Indoco Remedies Limited (INDOCO) · Syncom Formulation (India) Ltd. (SYNCOMF)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BETA in NSE Scanner →